Investors in cash trouble should check out ADMA Biologics Inc. (ADMA)

ADMA Biologics Inc. (NASDAQ: ADMA) stock fell -2.86% on Monday to $3.40 against a previous-day closing price of $3.50. With 3.24 million shares changed hands, the volume of the stock remained lighter than its average volume of 3.34 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.5000 whereas the lowest price it dropped to was $3.3600. The 52-week range on ADMA shows that it touched its highest point at $3.98 and its lowest point at $1.30 during that stretch. It currently has a 1-year price target of $5.12. Beta for the stock currently stands at 0.88.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Price Performance and Earnings:

Three-month performance surged to 31.78% while six-month performance rose 56.68%. The stock gained 137.76% in the past year, while it has lost -12.37% so far this year. A look at the trailing 12-month EPS for ADMA yields -0.36 with Next year EPS estimates of -0.18. For the next quarter, that number is -0.06. This implies an EPS growth rate of 41.60% for this year and 43.80% for next year.

Float and Shares Shorts:

At present, 196.38 million ADMA shares are outstanding with a float of 176.84 million shares on hand for trading. On Oct 13, 2022, short shares totaled 25.82 million, which was 13.15% higher than short shares on Sep 14, 2022. In addition to Mr. Adam S. Grossman as the firm’s Co-Founder, Pres, CEO & Director, Dr. Jerrold B. Grossman D.P.S., Ph.D. serves as its Co-Founder & Vice Chairman.

Institutional Ownership:

Through their ownership of 76.15% of ADMA’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 47.30% of ADMA, in contrast to 27.19% held by mutual funds. Shares owned by individuals account for 24.69%. As the largest shareholder in ADMA with 5.87% of the stake, BlackRock Fund Advisors holds 11,541,915 shares worth 11,541,915. A second-largest stockholder of ADMA, Perceptive Advisors LLC, holds 10,933,387 shares, controlling over 5.56% of the firm’s shares. Caligan Partners LP is the third largest shareholder in ADMA, holding 10,264,311 shares or 5.22% stake. With a 3.94% stake in ADMA, the SPDR S&P Biotech ETF is the largest stakeholder. A total of 7,757,979 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 3.17% of ADMA stock, is the second-largest Mutual Fund holder. It holds 6,244,828 shares valued at 24.23 million. iShares Russell 2000 ETF holds 2.10% of the stake in ADMA, owning 4,125,993 shares worth 16.01 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ADMA since 4 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ADMA analysts setting a high price target of $6.00 and a low target of $4.50, the average target price over the next 12 months is $5.13. Based on these targets, ADMA could surge 76.47% to reach the target high and rise by 32.35% to reach the target low. Reaching the average price target will result in a growth of 50.88% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. ADMA will report FY 2022 earnings on 03/22/2024. Analysts have provided yearly estimates in a range of -$0.30 being high and -$0.34 being low. For ADMA, this leads to a yearly average estimate of -$0.32. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. ADMA Biologics Inc. surprised analysts by -$0.00 when it reported -$0.08 EPS against a consensus estimate of -$0.08. The surprise factor in the prior quarter was $0.01. Based on analyst estimates, the high estimate for the next quarter is -$0.03 and the low estimate is -$0.08. The average estimate for the next quarter is thus -$0.06.

Summary of Insider Activity:

Insiders traded ADMA stock several times over the past three months with 3 Buys and 0 Sells. In these transactions, 36,958 shares were bought while 0 shares were sold. The number of buy transactions has increased to 10 while that of sell transactions has risen to 6 over the past year. The total number of shares bought during that period was 607,388 while 384,679 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *